Positron, a molecular imaging company specialising in the field of nuclear cardiology, has reported an increase in revenue of 439% for the third quarter ended 30 September 2010, compared to the prior year period.

Positron also reported an increase in operating expenses to $2.5m from $1.1m, compared the prior year period.

Over the past 12 months Positron has expended resources on the research and development of its two major business segments, including the development of Nuclear Cardio-Assist and radiopharmaceutical manufacturing facility, and sales and marketing efforts for the Attrius Cardiac PET system.

As a result of investments made, Positron expects a significant increase in sales of the Attrius Cardiac PET system and related service contracts, as well as sales of radiopharmaceuticals through the company’s dose dispensing systems, and the manufacturing of radiopharmaceuticals.

The company expects that these developments will have a positive impact on revenue and net margins.

Positron CEO Patrick Rooney said that they continue to execute their strategy of being the leader in cardiac PET, which they believe will yield positive revenue and earnings growth patterns over the long-term.

Positron products include: the Attrius, a PET imaging device; the Pulse, a SPECT imaging device; the Nuclear Pharm-Assist, an automated radiopharmaceutical distribution device; and the Tech-Assist, a radiopharmaceutical injection shield.